NKILT Therapeutics: next gen cell therapy to more cancer patients скачать в хорошем качестве

NKILT Therapeutics: next gen cell therapy to more cancer patients

As we are currently actively fundraising, NKILT's main audience is essentially investors (with more focus on Family Offices currently), and potential strategic partners (biotechs, small pharma and eventually academic partners). The company brings a novel off-the-shelf cell therapy to tackle over half of cancers across hematologic and solid tumors. The unique technology will allow to scale manufacturing in order to "democratize" cell therapy and build new treatments for more patients, globally, and make cell therapy accessible, affordable and down the road profitable. NKILT's unique proprietary binding technology (with US patent granted in Q2 2025, under fast track globally), called CIR™ (Chimeric ILT-Receptor), brings better outcome in targeting cancer cells and limit the risks of immune escape mechanisms used by cancer cells. It also allows engineered cells to deliver better outcome vs. standard CAR or antibody-based technologies. The initial focus is with NK cells, but the CIR™ technology is applicable to all immune cells (T cells, NKT cells, etc...). In addition, NKILT's second IP (under review currently), focused on activation of our cells and enhances significantly their ability to kill cancer cells (making them true serial killers of cancer cells), but also increases persistence of our cells so they can continuously deploy their serial killing ability for up to 6 week. With such technology, NKILT brings similar activity,. or even better, than existing anti-body-based technology, which could tackle large cancer population, like colorectal, esophegeal, bladder, breast, etc... and multiple hematologic malignancies.